Stereotaxis shares surge 13.12% premarket following FDA approval of MAGiC ablation catheter.

Stereotaxis surged 13.12% in premarket trading following FDA approval of its MAGiC Magnetic Interventional Ablation Catheter. The robotic magnetic catheter, designed for precise cardiac ablation in complex arrhythmia cases, expands access to minimally invasive treatments for underserved patient populations. The approval marks a pivotal advancement in robotic electrophysiology, with company leadership and clinicians highlighting its potential to enhance procedural outcomes and broaden adoption of magnetic navigation technology. This regulatory milestone reinforces Stereotaxis’ position as a leader in surgical robotics for interventional cardiology, aligning with the stock’s significant premarket gain.